Lung Cancer Clinical Trial
The Neuroendocrine Effects of Pioglitazone in Patients With Lung Cancer and Cachexia
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with advanced non-small-cell lung cancer and cachexia.
Age â‰¥18 years
Documented histologic or cytologic diagnosis of non-small-cell lung cancer that is locally advanced and inoperable or metastatic (e.g., spread to distant organs)
Cachexia defined by Fearon criteria
Insulin resistance syndrome, defined with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Ability to provide written informed consent, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures
Provide written approval by a qualified healthcare professional
Allow the collection and storage of biospecimens and data for future use
Prior diagnosis of type 2 diabetes
Prior or current thiazolidinedione (TZD) therapy
Known hypersensitivity to TZD
New York Heart Association (NYHA) class I-IV heart failure
History of or actively treated bladder cancer
Current use of CYP2C inhibitor (e.g., gemfibrozil) or CYP2C inducer (e.g., rifampin)
Inadequate hepatic function
Currently pregnant, breastfeeding, or planning to become pregnant within the next 16 weeks
Contraindications to magnetic resonance imaging (e.g., implanted cardiac device, cochlear implant)
Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.